Journal
LEUKEMIA & LYMPHOMA
Volume 62, Issue 12, Pages 2845-2853Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1941929
Keywords
ALK; B-cell lymphoma; CD20-negative
Categories
Ask authors/readers for more resources
ALK+ large B-cell lymphoma is rare and aggressive, with male predominance and not associated with chronic viral infections. The prognosis is poor, but early disease stage is associated with better outcomes. Additional research is needed to better understand and treat this condition.
Anaplastic lymphoma kinase-positive (ALK+) large B-cell lymphoma (LBCL) is a rare CD20-negative aggressive lymphoma. Given its rarity, data on ALK + LBCL are scarce and limited to case reports and small case series. Our systematic review included 184 unique cases published in the literature and shows that ALK + LBCL can affect individuals at any age, has a male predominance and is not associated with chronic viral infections. The malignant cells express ALK, VS38c, BLIMP-1, EMA, c-MYC, and BOB-1. The STAT3/STAT5, PI3K/AKT, PLCG2, and ERK pathways are important in the pathophysiology of ALK + LBCL. The prognosis of ALK + LBCL is poor with a 5-year survival rate of 28%. Early disease stage is associated with better outcomes. ALK inhibitors and other targeted agents could be of value in the treatment of ALK + LBCL. Additional research is needed to better understand, diagnose and treat ALK + LBCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available